Abstract: The present invention provides pharmaceutical formulations comprising an antibody that specifically binds to angiopoietin 2 (Ang-2). The formulations may contain, in addition to an anti-Ang-2 antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months and after being subjected to thermal and other physical stress.
Abstract: The present invention provides a method of treatment or prophylaxis of enteric disease caused by Gram negative bacteria. The method includes the step of administering a vaccine or a hyperimmune material raised against said vaccine to an individual. The vaccine comprises one or more cell wall antigens reactive in a manner characteristic of O group serotypes, or reactive in a manner characteristic of lipopolysaccharide associated antigens, and at least some of said antigens are separated from bacterial cell walls or wall fragments. The invention also provides composition containing hyperimmune material as well as uses of the composition and vaccine.
Type:
Grant
Filed:
December 23, 2013
Date of Patent:
August 2, 2016
Assignee:
Immuron Limited
Inventors:
Roy Michael Robins-Browne, Grant Thomas Rawlin, Gottfried Lichti
Abstract: This invention relates to methods for selecting a treatment, treating, and predicting survival time in subjects with cancer, such as colorectal cancer, based on tumor expression levels of chemokines, cytotoxic genes, and/or dendritic cell genes.
Type:
Grant
Filed:
January 28, 2011
Date of Patent:
August 2, 2016
Assignee:
H. Lee Moffitt Cancer Center and Research Institute, Inc.
Inventors:
James J. Mulé, Domenico Coppola, Timothy J. Yeatman, Andrey Loboda, Michael V. Nebozhyn
Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain without affecting glycemic control. In particular, the invention provides novel glucagon analog peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the glucagon-like peptide-1 (GLP-1) receptor as compared to human glucagon.
Type:
Grant
Filed:
June 23, 2011
Date of Patent:
August 2, 2016
Assignee:
Zealand Pharma A/S
Inventors:
Eddi Meier, Ditte Riber, Jens Rosengren Daugaard, Marie Skovgaard
Abstract: An object of the present invention is to create a novel engineered Protein A ligand having better antibody dissociation properties in the presence of an acid than conventional engineered Protein A ligands and a further object of the present invention is to create a novel engineered Protein A ligand having higher alkali resistance. The present invention is to provide a protein having an affinity for an immunoglobulin, including an amino acid sequence derived from any of E, D, A, B and C domains of Protein A, wherein at least one Gly residue in the amino acid sequence is replaced with an amino acid other than Ala, and the protein has a lower affinity for an Fab region of an immunoglobulin than a protein including an amino acid sequence in which the Gly residue is replaced with Ala. Also, the present invention is to provide the protein having an affinity for an immunoglobulin, which has improved chemical stability in an alkaline condition compared to the corresponding domain.
Abstract: Compositions and methods for treating infectious diseases produced by biofilms are disclosed. More specifically, the present disclosure refers to pharmaceutical compositions which may be used for treating biofilm infections, specifically, biofilms formed by bacteria such as Pseudomonas, E. coli, Klebsiella, and other human pathogens. Pharmaceutical compositions may include a nutrient dispersion. Pharmaceutical compositions disclosed may employ chemotactic agents in order to disrupt biofilms and therefore enhance the antibiotic response. Pharmaceutical compositions disclosed may include suitable vehicles which may depend on the dosage form.
Type:
Grant
Filed:
May 22, 2013
Date of Patent:
July 12, 2016
Assignee:
Professional Compounding Centers of America (PCCA)
Abstract: The present invention provides a method for stable long-term storage of non-glycosylated recombinant human Granulocyte-Colony Stimulating Factor (G-CSF), wherein an aqueous acetate or glutamate buffered G-CSF composition containing the non-glycosylated recombinant human G-CSF and sorbital is cooled to a temperature of ?15° C. or below to obtain a frozen G-CSF composition, which frozen composition is then stored in the frozen state and then increased in temperature to a temperature within the range of from 2° C. to 8° C. for a period of time adjusted to allow the composition to thaw and to obtain a liquid composition having a G-CSF content of at least 95% of the G-CSF content of the original composition.
Type:
Grant
Filed:
June 17, 2014
Date of Patent:
July 12, 2016
Assignee:
Sandoz AG
Inventors:
Klaus Graumann, Helmut Lerch, Thomas Lauber
Abstract: Described herein are compositions and methods related to antigen binding proteins that bind to human ST2, including antibodies. In particular embodiments, the disclosure provides fully human anti-ST2 antibodies and deriviatives and variants thereof. Further provided are nucleic acids encoding such antibodies and antibody fragments, variants, and derivatives. Also, provided are methods of making and using such antibodies including methods of treating and preventing autoimmune and inflammatory disorders.
Type:
Grant
Filed:
May 17, 2013
Date of Patent:
July 5, 2016
Assignee:
Amgen Inc.
Inventors:
Dirk E. Smith, Ian Foltz, Chadwick T. King, Ai Ching Lim, Rutilio Clark, Michael R. Comeau, Randal R. Ketchem, Donghui Shi, Xiaoshan Min, Zhulun Wang
Abstract: Disclosed herein are methods and kits which are useful for detecting presence of an enzyme in a test sample based upon the intrinsic enzymatic activity of such test sample. The present invention provides the ability to evaluate cell culture conditions and optimize the desired glycoform content of recombinantly prepared enzymes.
Abstract: Mutant Listeria bacteria that modulate interferon-? production are provided. The subject bacteria are characterized by having a mutation in a gene chosen from a TetR gene, a LadR gene, a VirR gene, a MarR gene a MdrL gene, a MdrT gene and a MdrM gene. The subject bacteria find use in a variety of applications, where representative applications of interest include, but are not limited to: (a) use of the subject bacteria as adjuvants; (b) use of the subject bacteria as delivery vectors for introducing macromolecules into a cell; (c) use of the subject bacteria as vaccines for eliciting or boosting a cellular immune response; etc.
Type:
Grant
Filed:
June 16, 2015
Date of Patent:
July 5, 2016
Assignee:
The Regents of the University of California
Inventors:
Daniel A. Portnoy, Anat A. Herskovits, Gregory Crimmins
Abstract: The present invention provides aptamer-modified polymers and materials thereof, which may be used for the binding of factors in a wound bed. For example, the aptamer-modified materials can be polypeptides conjugated to polymer foam materials. Such materials may be used, for example, for dressings, wound inserts, or pads.
Type:
Grant
Filed:
April 27, 2012
Date of Patent:
July 5, 2016
Assignee:
KCI LICENSING, INC.
Inventors:
James Courage, Diwi Allen, Amy McNulty, Anthony Rycerz, Christopher Carroll, Douglas Hanson, Todd Fruchterman
Abstract: The present invention relates to methods of inducing an immune response to Staphylococcus comprising administering a composition comprising an SA2493-related polypeptide from Staphylococcus aureus as well as derivatives or fragments thereof. The present invention also encompasses methods of treating and/or reducing the likelihood of a Staphylococcus infection by administering a composition comprising an SA2493-related polypeptide or an antibody that specifically binds to an SA2493 polypeptide, derivative or fragments thereof. Compositions administered in the methods of the invention can include one or more additional antigens including, but not limited to, IsdB. Compositions used to practice the methods of the invention are also encompassed.
Type:
Grant
Filed:
July 9, 2013
Date of Patent:
June 28, 2016
Assignee:
Merck Sharp & Dohme Corp.
Inventors:
Tessie B. McNeely, Leslie Cope, Gregory D. Pancari, Amita Joshi
Abstract: Interleukin 18 (IL-18) participates in both innate and acquired immunity. The bioactivity of IL-18 is negatively regulated by the IL-18 binding protein (IL18BP), a naturally occurring and highly specific inhibitor. This soluble protein forms a complex with free IL-18 preventing its interaction with the IL-18 receptor, thus neutralizing and inhibiting its biological activity. The present invention discloses binding molecules, in particular antibodies or fragments thereof, which bind IL-18 and do not bind IL-18 bound to IL-18BP (IL-18/IL-18BP complex). Apart from its physiological role, IL-18 has been shown to mediate a variety of autoimmune and inflammatory diseases. The binding molecules of the inventions may be used as therapeutic molecules for treating IL-18-related autoimmune and inflammatory diseases or as diagnostic tools for characterizing, detecting and/or measuring IL-18 not bound to IL-18BP as component of the total IL-18 pool.
Type:
Grant
Filed:
September 4, 2013
Date of Patent:
June 28, 2016
Assignee:
Novartis AG
Inventors:
Michael Otto Bardroff, Barbara Brannetti, Emma Michelle Campbell, Beate Diefenbach-Streiber, Adina Eberth, Christian Carsten Silvester Kunz, Sylwia Marshall, Jean-Michel Rene Rondeau, Jean-Marc Alfred Schlaeppi, Gino Anselmus Van Heeke
Abstract: The present invention pertains to a composition containing an immunogenic cell preparation of killed Leptospira bacteria in a citric acid solution. It also pertains to a vaccine to protect an animal against an infection with Leptospira bacteria, wherein the vaccine comprises this composition, and to the use of citric acid to stabilize an immunogenic preparation of killed Leptospira bacteria in a liquid carrier, by dissolving the citric acid in the carrier.
Type:
Grant
Filed:
August 16, 2013
Date of Patent:
June 28, 2016
Assignee:
Intervet Inc.
Inventors:
Henricus Leo Bernardus Maria Klaasen, Peter Loeffen, Eric Onno Rijke
Abstract: A high throughput bioluminescence mutant screening procedure is disclosed. This procedure utilizes robotics, and bacterial luciferase to allow real-time monitoring of mutant viability. The procedure was used to decelop a live attenuated vaccine for a catfish against E. ictaluri, which is further claimed herein. Additionally, genes from other bacterial species are disclosed which may also be used to create vaccines.
Abstract: Provided are stable protein formulations that contain at least one amino acid. In certain embodiments, amino acid combinations either at least two, or three, or four, or more amino acids are included. By virtue of inclusion of the amino acids, the formulation has low viscosity and a protein in the formulations is physically, chemically, and biological stable even at high concentrations. In further embodiments, by virtue of inclusion of the amino acids, a protein in the formulations is physically, chemically, and biological stable even at high concentrations.
Abstract: Methods for stimulating immune responses in a bovine animal susceptible to infection by Leptospira hardjo-bovis are disclosed. In the methods, a composition of inactivated L. hardjo-bovis and an adjuvant is administered to the animal within about 4 weeks of birth. The immune responses stimulated in the animal prevent or shorten the duration of a subsequent L. hardjo-bovis infection. The immune response is effective for at least a year.
Abstract: The invention relates to novel polypeptides which are recognized by anti-Trichinella antibodies. Said polypeptides can be used particularly for detecting anti-Trichinella antibodies and in trichinosis prevention.
Type:
Grant
Filed:
February 16, 2011
Date of Patent:
June 7, 2016
Assignee:
Agence Nationale de Securite Sanitaire de l'Alimentation, de l'Environnement et du Travail
Inventors:
Aleksandar Zocevic, Baldissera Giovani, Sandrine A. Lacour, Pauline Macé, Isabelle Vallée, Pascal Boireau
Abstract: The present invention provides isolated polypeptides isolatable from a Yersinia spp. Also provided by the present invention are compositions that include one or more of the polypeptides, and methods for making and methods for using the polypeptides.
Type:
Grant
Filed:
November 5, 2015
Date of Patent:
May 31, 2016
Assignee:
EPITOPIX, LLC
Inventors:
Daryll A. Emery, Darren E. Straub, Laura Wonderling
Abstract: The present application provides compositions and methods useful for treating and diagnosing diseases and disorders associated with moesin activation.